---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-099017"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T10:49:30.605259+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics appoints Ryan Maynard as CFO, effective Sept 12, 2022

## Summary
- Ryan Maynard appointed CFO effective September 12, 2022; principal financial and accounting officer.
- Compensation: $460,000 base salary, 40% target bonus, 225,000 share option grant vesting over 4 years.
- Maynard previously CFO of LetsGetChecked and Rigel Pharmaceuticals (10 years as CFO at Rigel).
- Appointment aligns with ongoing launch of KORSUVA injection for chronic pruritus.

## SEC filing metadata
- accession: 0001104659-22-099017
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/0001104659-22-099017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/tm2225550d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-099017
- JSON: https://secwatch.observer/filing/0001104659-22-099017.json
- Plain text: https://secwatch.observer/filing/0001104659-22-099017.txt

## Key facts
- Executive change
  Ryan Maynard was appointed as Chief Financial Officer at Tvardi Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/0001104659-22-099017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.